FDA Drug · D-0727-2026

Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL), Twenty-five, 20 mL Single-Dose Vials, Rx only, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-286-23; NDC Vial: 63323-286-05

Class II · Ongoing

Presence of Particulate Matter: Hair was found in products

Affected lots / codes — check yours against thisLot #: 6133436, Exp. Date 10/2028

Recalling firm: Fresenius Kabi USA, LLC, Lake Zurich, IL
Classification: Class II (temporary or reversible harm possible)
Status: Ongoing
Quantity: 92,600 vials
Distribution: Nationwide within in the USA
Recall initiated: July 16, 2026
Classified: July 23, 2026
Initiation: Voluntary: Firm initiated

Official source. This record is published by the U.S. FDA through the openFDA enforcement database. View the unmodified government record:
https://api.fda.gov/drug/enforcement.json?search=recall_number%3A%22D-0727-2026%22

Important. Recalls target specific lots and codes — compare the affected lots above against your own product. This page reproduces public FDA data for readability; EveryRecall is independent and not affiliated with the FDA.

Check this brand across all 8 databases →